Journal of Molecular and Cellular Cardiology Plus
Overview
Journal of Molecular and Cellular Cardiology Plus is a scientific journal, published since 2022 in English. The journal's country of origin is United Kingdom.
Details
Details
Abbr.
J Mol Cell Cardiol Plus
Start
2022
End
Continuing
Frequency
Quarterly
e-ISSN
2772-9761
Country
United Kingdom
Language
English
Recent Articles
1.
Wu Q, Gille C, Maderspacher F, Hildebrand B, Thienel M, Clauss S
J Mol Cell Cardiol Plus
. 2025 Mar;
11:100287.
PMID: 40028176
Thrombosis and thromboembolism are serious clinical complications of cardiovascular diseases and are among the leading causes of mortality worldwide. Dysregulation of the renin-angiotensin system is associated with an increased incidence...
2.
Phair I, Sovakova M, Alqurashi N, Nisr R, McNeilly A, Lamont D, et al.
J Mol Cell Cardiol Plus
. 2025 Feb;
11:100285.
PMID: 39991505
In patients with stable coronary artery disease, plasma levels of 7-ketocholesterol (7-KC), found at high levels in atherosclerotic lesions, predict risk of incident heart failure dose dependently, potentially contributing to...
3.
Mantyla T, Wang C, Hanninen M, Immonen K, Jantti T, Lassus J, et al.
J Mol Cell Cardiol Plus
. 2025 Feb;
11:100284.
PMID: 39927096
Cardiogenic shock (CS) is a medical emergency with high in-hospital mortality. New biomarkers are needed to identify patients at a greater risk of adverse outcomes. This study aimed to investigate...
4.
Maxwell C, Bhakta N, Denniff M, Sandhu J, Kessler T, Ng L, et al.
J Mol Cell Cardiol Plus
. 2025 Feb;
11:100283.
PMID: 39895831
Despite strong causal associations with cardiovascular and metabolic disorders including coronary artery disease, hypertension, and type 2 diabetes, as well as a range of other diseases, the exact function of...
5.
Dimasi C, Darby J, Holman S, Quinn M, Meakin A, Seed M, et al.
J Mol Cell Cardiol Plus
. 2025 Jan;
9():100084.
PMID: 39803591
The adult mammalian heart is unable to undergo cardiac repair, limiting potential treatment options after cardiac damage. However, the fetal heart is capable of cardiac repair. In preparation for birth,...
6.
Korn A, Simsek S, Fiet M, Waas I, Niessen H, Krijnen P
J Mol Cell Cardiol Plus
. 2025 Jan;
9():100083.
PMID: 39803590
Aims: Diabetes mellitus (DM) induces increased inflammation of atherosclerotic plaques, resulting in elevated plaque instability. Mesenchymal stem cell (MSC) therapy was shown to decrease plaque size and increase stability in...
7.
Lees J, Greening D, Rudd D, Cross J, Rosdah A, Lai X, et al.
J Mol Cell Cardiol Plus
. 2025 Jan;
9():100085.
PMID: 39803589
Dynamin-related protein 1 (Drp1) is a mitochondrial fission protein and a viable target for cardioprotection against myocardial ischaemia-reperfusion injury. Here, we reported a novel Drp1 inhibitor (DRP1i1), delivered using a...
8.
Gumanova N, Vasilyev D, Bogdanova N, Havrichenko Y, Drapkina O
J Mol Cell Cardiol Plus
. 2025 Jan;
9():100091.
PMID: 39803588
Background And Aims: Cadherins are adhesion proteins, and their dysregulation may result in the development of atherosclerosis, plaque rupture, or lesions of the vascular wall. The aim of the present...
9.
Herting J, Berg A, Hadova K, Heinick A, Konig S, Kuhlmann M, et al.
J Mol Cell Cardiol Plus
. 2025 Jan;
3():100030.
PMID: 39803363
Protein phosphatase 2A (PP2A) plays a central role in myocardial ischemia-reperfusion (I/R) injury. Several studies showed a detrimental function of PP2A by using either overexpression models of the catalytic subunit...
10.
Lu Z, Zhuang L, Zhang R, Chen K, Zhang H, Yan X
J Mol Cell Cardiol Plus
. 2025 Jan;
3():100028.
PMID: 39803362
No abstract available.